These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 34147625)

  • 1. The potential of mechanistic information organised within the AOP framework to increase regulatory uptake of the developmental neurotoxicity (DNT) in vitro battery of assays.
    Sachana M; Willett C; Pistollato F; Bal-Price A
    Reprod Toxicol; 2021 Aug; 103():159-170. PubMed ID: 34147625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Regulatory and Scientific Effort for Improved Developmental Neurotoxicity Testing.
    Sachana M; Bal-Price A; Crofton KM; Bennekou SH; Shafer TJ; Behl M; Terron A
    Toxicol Sci; 2019 Jan; 167(1):45-57. PubMed ID: 30476307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Toward a Better Testing Paradigm for Developmental Neurotoxicity: OECD Efforts and Regulatory Considerations.
    Sachana M; Shafer TJ; Terron A
    Biology (Basel); 2021 Jan; 10(2):. PubMed ID: 33498772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to improve the regulatory assessment of developmental neurotoxicity (DNT) using in vitro methods.
    Bal-Price A; Pistollato F; Sachana M; Bopp SK; Munn S; Worth A
    Toxicol Appl Pharmacol; 2018 Sep; 354():7-18. PubMed ID: 29476865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated Approaches to Testing and Assessment: OECD Activities on the Development and Use of Adverse Outcome Pathways and Case Studies.
    Sakuratani Y; Horie M; Leinala E
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123 Suppl 5():20-28. PubMed ID: 29316278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of developmental neurotoxicity induced by chemical mixtures using an adverse outcome pathway concept.
    Pistollato F; de Gyves EM; Carpi D; Bopp SK; Nunes C; Worth A; Bal-Price A
    Environ Health; 2020 Feb; 19(1):23. PubMed ID: 32093744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An industry perspective: A streamlined screening strategy using alternative models for chemical assessment of developmental neurotoxicity.
    Li J; Settivari R; LeBaron MJ; Marty MS
    Neurotoxicology; 2019 Jul; 73():17-30. PubMed ID: 30786249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of neurotoxicology (NT)/developmental neurotoxicology (DNT) adverse outcome pathways and key event linkages with in vitro DNT screening assays.
    Pitzer EM; Shafer TJ; Herr DW
    Neurotoxicology; 2023 Dec; 99():184-194. PubMed ID: 37866692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Availability of Stem Cell-Based In Vitro Methods for Developmental Neurotoxicity (DNT) Testing.
    Fritsche E; Barenys M; Klose J; Masjosthusmann S; Nimtz L; Schmuck M; Wuttke S; Tigges J
    Toxicol Sci; 2018 Sep; 165(1):21-30. PubMed ID: 29982830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes.
    Bal-Price A; Crofton KM; Leist M; Allen S; Arand M; Buetler T; Delrue N; FitzGerald RE; Hartung T; Heinonen T; Hogberg H; Bennekou SH; Lichtensteiger W; Oggier D; Paparella M; Axelstad M; Piersma A; Rached E; Schilter B; Schmuck G; Stoppini L; Tongiorgi E; Tiramani M; Monnet-Tschudi F; Wilks MF; Ylikomi T; Fritsche E
    Arch Toxicol; 2015 Feb; 89(2):269-87. PubMed ID: 25618548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of the Adverse Outcome Pathway (AOP): Chronic binding of antagonist to N-methyl-d-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children.
    Sachana M; Rolaki A; Bal-Price A
    Toxicol Appl Pharmacol; 2018 Sep; 354():153-175. PubMed ID: 29524501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA).
    Tollefsen KE; Scholz S; Cronin MT; Edwards SW; de Knecht J; Crofton K; Garcia-Reyero N; Hartung T; Worth A; Patlewicz G
    Regul Toxicol Pharmacol; 2014 Dec; 70(3):629-40. PubMed ID: 25261300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the adverse outcome pathway concept for investigating developmental neurotoxicity potential of Chinese herbal medicines by using human neural progenitor cells in vitro.
    Klose J; Li L; Pahl M; Bendt F; Hübenthal U; Jüngst C; Petzsch P; Schauss A; Köhrer K; Leung PC; Wang CC; Koch K; Tigges J; Fan X; Fritsche E
    Cell Biol Toxicol; 2023 Feb; 39(1):319-343. PubMed ID: 35701726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinoids and developmental neurotoxicity: Utilizing toxicogenomics to enhance adverse outcome pathways and testing strategies.
    Chen H; Chidboy MA; Robinson JF
    Reprod Toxicol; 2020 Sep; 96():102-113. PubMed ID: 32544423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scientific Validation of Human Neurosphere Assays for Developmental Neurotoxicity Evaluation.
    Koch K; Bartmann K; Hartmann J; Kapr J; Klose J; Kuchovská E; Pahl M; Schlüppmann K; Zühr E; Fritsche E
    Front Toxicol; 2022; 4():816370. PubMed ID: 35295221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probabilistic modelling of developmental neurotoxicity based on a simplified adverse outcome pathway network.
    Spînu N; Cronin MTD; Lao J; Bal-Price A; Campia I; Enoch SJ; Madden JC; Mora Lagares L; Novič M; Pamies D; Scholz S; Villeneuve DL; Worth AP
    Comput Toxicol; 2022 Feb; 21():100206. PubMed ID: 35211661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny - part II: how can key events of relevant adverse outcome pathways be addressed in toxicological assessments?
    Marty S; Beekhuijzen M; Charlton A; Hallmark N; Hannas BR; Jacobi S; Melching-Kollmuss S; Sauer UG; Sheets LP; Strauss V; Urbisch D; Botham PA; van Ravenzwaay B
    Crit Rev Toxicol; 2021 Apr; 51(4):328-358. PubMed ID: 34074207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes.
    Fritsche E; Grandjean P; Crofton KM; Aschner M; Goldberg A; Heinonen T; Hessel EVS; Hogberg HT; Bennekou SH; Lein PJ; Leist M; Mundy WR; Paparella M; Piersma AH; Sachana M; Schmuck G; Solecki R; Terron A; Monnet-Tschudi F; Wilks MF; Witters H; Zurich MG; Bal-Price A
    Toxicol Appl Pharmacol; 2018 Sep; 354():3-6. PubMed ID: 29447839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A high-level overview of the OECD AOP Development Programme.
    Chauhan V; Hamada N; Wilkins R; Garnier-Laplace J; Laurier D; Beaton D; Tollefsen KE
    Int J Radiat Biol; 2022; 98(12):1704-1713. PubMed ID: 35938955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards a regulatory use of alternative developmental neurotoxicity testing (DNT).
    Terron A; Bennekou SH
    Toxicol Appl Pharmacol; 2018 Sep; 354():19-23. PubMed ID: 29454059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.